Two Sigma Securities’s Rigel Pharmaceuticals RIGL Stock Holding History

Two Sigma Securities’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,195	Closed	-$60.8K	–	3536
2023 Q4	$60.8K	Buy	+4,195	New	+$42.9K	﹤0.01%	2582
2023 Q2	–	Sell	-2,881	Closed	-$38K	–	3251
2023 Q1	$38K	Buy	+2,881	New	+$45.8K	﹤0.01%	2297
2022 Q3	–	Sell	-3,647	Closed	-$41K	–	3015
2022 Q2	$41K	Buy	+3,647	New	+$73.2K	﹤0.01%	1871
2020 Q3	–	Sell	-3,721	Closed	-$68K	–	1604
2020 Q2	$68K	Buy	+3,721	New	+$66.9K	﹤0.01%	1239
2019 Q2	–	Sell	-1,581	Closed	-$41K	–	2364
2019 Q1	$41K	Sell	1,581 -942	-37%	-$21.5K	﹤0.01%	1630
2018 Q4	$58K	Sell	2,523 -1,081	-30%	-$30.5K	﹤0.01%	1922
2018 Q3	$116K	Buy	+3,604	New	+$108K	﹤0.01%	2273
2017 Q1	–	Sell	-1,470	Closed	-$35K	–	1088
2016 Q4	$35K	Buy	+1,470	New	+$42.1K	0.01%	623

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Securities's RIGL Position: Q1 2024 in Review

Two Sigma Securities sold out of Rigel Pharmaceuticals (RIGL) in Q1 2024, closing a stake of 4,195 shares — an estimated $60.8K sold.

Two Sigma Securities first reported a position in RIGL in Q4 2016 and held it in 8 quarters. The position peaked at $116K in Q3 2018. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2024.

Two Sigma Securities reported no remaining Rigel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Two Sigma Securities sold 4,195 Rigel Pharmaceuticals shares in Q1 2024, an estimated $60.8K.
Two Sigma Securities first reported a position in Rigel Pharmaceuticals in Q4 2016 and held it in 8 quarters.
Two Sigma Securities's Rigel Pharmaceuticals position peaked at $116K in Q3 2018.
117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2024.

Based on Two Sigma Securities's 13F filing for Q1 2024, filed 15 May 2024.